Speaker Series Summary Episode 6:

Posted on

Current Treatment Options​ for GBS, CIDP, MMN, and Variants

In this episode of our Speaker Series, we dive into the world of treatments for GBS, CIDP, and MMN as well as understanding them from Dr. Saperstein, a neurologist on our Global Medical Advisory Board.


Two main treatments: Plasmapheresis or IVIg/Subcutaneous Infusion

Is there ever a circumstance where GBS is not treated with IVIg?

What if a patient does not respond to the first round of IVIg?

Long Term Treatments


What is the difference between On label and Off label medications and how does it affect CIDP?

Subcutaneous Treatment or SCIg


Hyqvia (Brand of IVIG; administered Subcutaneously)

What are some alternatives to IG (Immunoglobin)?





Waiting for FDA Approval


Other Potential Therapies

Relevant Resources

Treatment guidelines – https://www.gbs-cidp.org/gbscidp-guidelines-for-treatment-and-diagnosis/

Treatments & Access page – https://www.gbs-cidp.org/treatments-access/

Centers of Excellence – https://www.gbs-cidp.org/support/centers-of-excellence/

Doctor to Doctor consult https://www.gbs-cidp.org/doctor-to-doctor/

*Special thanks to Dr. David Saperstein, MD – Director of the Center for Complex Neurology, EDS & POTS